These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38289577)

  • 41. Lowering cholesterol in chronic kidney disease: is it safe and effective?
    Wong MG; Wanner C; Knight J; Perkovic V
    Eur Heart J; 2015 Nov; 36(43):2988-95. PubMed ID: 26289904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Ezetimibe as a treatment for dyslipidaemia in CKD].
    Żebrowski P; Kaszyńska M
    Wiad Lek; 2019; 72(11 cz 2):2210-2213. PubMed ID: 31860838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current and future options in cholesterol lowering treatments.
    Elis A
    Eur J Intern Med; 2023 Jun; 112():1-5. PubMed ID: 36813611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence-based goals in LDL-C reduction.
    Soran H; Dent R; Durrington P
    Clin Res Cardiol; 2017 Apr; 106(4):237-248. PubMed ID: 28124099
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements-A Narrative Review.
    Zivkovic S; Maric G; Cvetinovic N; Lepojevic-Stefanovic D; Bozic Cvijan B
    Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986246
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiovascular disease and its relationship with chronic kidney disease.
    Liu M; Li XC; Lu L; Cao Y; Sun RR; Chen S; Zhang PY
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(19):2918-26. PubMed ID: 25339487
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
    Mathew RO; Rosenson RS; Lyubarova R; Chaudhry R; Costa SP; Bangalore S; Sidhu MS
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):479-489. PubMed ID: 32556851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
    Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
    Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.
    Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Nabavi SM; Lavie CJ; Banach M;
    Prog Cardiovasc Dis; 2021; 67():65-74. PubMed ID: 33383060
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dyslipidemia in patients with chronic kidney disease.
    Hager MR; Narla AD; Tannock LR
    Rev Endocr Metab Disord; 2017 Mar; 18(1):29-40. PubMed ID: 28000009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
    Duprez DA; Handelsman Y; Koren M
    Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-density lipoprotein cholesterol lowering treatment: the current approach.
    Crismaru I; Pantea Stoian A; Bratu OG; Gaman MA; Stanescu AMA; Bacalbasa N; Diaconu CC
    Lipids Health Dis; 2020 May; 19(1):85. PubMed ID: 32375792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
    Ridker PM; Amarenco P; Brunell R; Glynn RJ; Jukema JW; Kastelein JJ; Koenig W; Nissen S; Revkin J; Santos RD; Schwartz PF; Yunis C; Tardif JC;
    Am Heart J; 2016 Aug; 178():135-44. PubMed ID: 27502861
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New Drugs for Lowering LDL-Cholesterol.
    Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.
    Ali S; Dave N; Virani SS; Navaneethan SD
    Curr Atheroscler Rep; 2019 Jun; 21(9):32. PubMed ID: 31230129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
    Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
    Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.